Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: A retrospective study

Minerva Endocrinologica

Volumn 34, Issue 3, 2009, Pages 195-203

  Pedrazzini, L ^a   Baroli, A ^a   Lomuscio, G ^a   Marzoli, L ^a  

^a Circolo Hospital   (Italy)

Author keywords

Anti thyroglobulin; Thyroglobulin; Thyroid neoplasms

Indexed keywords

THYROGLOBULIN; THYROGLOBULIN ANTIBODY; TUMOR MARKER; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY; RADIOACTIVE IODINE;

ADULT; ANTIBODY TITER; ARTICLE; CANCER RECURRENCE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTIC THYROIDITIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; THYROID CARCINOMA; THYROIDECTOMY; ADOLESCENT; AGED; CHILD; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PAPILLARY CARCINOMA; PREDICTION AND FORECASTING; PRESCHOOL CHILD; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 77949909805     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sherman SI, Angelos P, Ball QW, Beenken SW. Thyrod carcinoma. J Natl Compr Canc Netw 2007;5:568-621
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W et al. European Consensus for the management of patients with differentiated thyroid cacinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. (Pubitemid 43997716)
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
4. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-75. (Pubitemid 41415459)
5. Spencer CA, Lo Presti JS. Technology insight: measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008:4:223-33.
6. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7. (Pubitemid 28496379)
7. De Groot IJ, Hoye K, Refetoff S, Van Herle AJ, Asteris GT, Rochman H. Serum antigen and antibodies in the diagnosis of thyroid cancer. J Clin Endocrinol Metab 1977;45:1220-3. (Pubitemid 8253448)
8. Ericsson UB, Christensen SR, Thorell JI. A high prevalence of thyroglobulin autoantibodies in adult with and without thyroid disease as measured with sensitive solid-phase immunosorbent radioassay. Clin Immunol Immunopathol 1985;37:154-62.
9. Pacini F, Mariotti S, Formica N, Elisei R, Anelli S, Capotorti E et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumor outcome. Acta Endocrinol 1988;119:373-80.
10. Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 1990;13:737-42.
11. Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B. Clinical meaning of circulating anti-thyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1992;33:1478-80.
12. Chiovato L, Latrofa F, Braverman LE, Pacini F et al. Disappearance of humoral thyroid autoimmunuty after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-51. (Pubitemid 38124590)
13. Görges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005;153:49-55.
14. Shah DH, Shrihari U, Dandekar SR, Vijayan U, Sharma SM. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid 2004;4:199-202.
15. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008;93:4683-9.
16. Feldt-Rasmussen U, Bech K, Date J, Hyltoft Pedersen P, Johansen K, Nistrup Madsen S. Thyroid stimulating antibodies, thyroglobulin antibodies and serum proteins during treatment of Graves' disease with radioiodine or propylthiouracil. Allergy 1982;37:161-7.
17. Feldt-Rasmussen U, Petersen PH, Date J, Madsen CM. Sequential changes in serum thyroglobulin (Tg) and its autoantibodies (TgAb) following subtotal thyroidectomy of patients with preoperatively detectable TgAb. Clin Endocrinol (Oxf) 1980;12:29-38.
18. Tumino S, Belfiore A. Appearance of antithyroglobulin antibodies as the sole sign of metastatic lymph nodes in a patient operated on for papillary thyroid cancer. Thyroid 2000;10:431-3.
19. McLachlan SM, Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies. Thyroid 2004;14:510-20.
20. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA et al. Serum thyrotropin, thyroxine, and thyroid antibodies in United States population (1998 to 1994): NHAMES III. J Clin Endocrinol Metab 2002;87:489-99.
21. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002;57:215-21.
22. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:57-67.
23. Weightman DR, Mallick UK, Fenwick JD, Perros P. Discordant seruma thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up. Cancer 2001;98:41-7. (Pubitemid 36741123)
24. Chinnappa P, Taguba L, Arciaga R, Faiman C, Siperstein A, Mehta AE et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab 2004;89:3705-9. (Pubitemid 39071460)
25. Grammatopoulos D, Elliott Y, Smith SC, Brown I, Grieve RJ, Hillhouse EW et al. Measurement of thyroglobulin mRNA in peripheral blood as an andjunctive test for monitoring thyroid cancer patients. Mol Pathol 2003;56:162-6.
26. Elisei R, Vivaldi A, Agate L, Molinaro E, Nencetti C, Grasso L et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of the differentiated thyroid cancer patients. J Clin Endocrinol Metab 2004;89:33-9.
27. Park EK, Chung JK, Lim IH, Park do J, Lee DS, Lee MC, Cho BY. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy 1-131 whole body scans. Eur J Nucl Med Mol Imaging 2009;36:171-9.
28. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:458-63.
29. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998;8:197-202.
30. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 1999;126:1070-7.
31. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S et al. Increased incidence of well differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 2007;204:764-73. (Pubitemid 46661188)
32. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 2008;150:49-52.